CLAIMS

1. Use of an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~A method~~ for preventing and/or treating a disease associated with a reduced density of interferon receptors~~, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof~~.

2. The use~~method~~ of claim 1, wherein said disease is selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis.

3. The use~~method~~ of claim 1, wherein said prevention and/or treatment is performed by overcoming a resistance to therapy with interferon and/or by compensating a reduced expression level of interferon receptors in a long-term therapy with interferon.

4. The use~~method~~ of claim 1, wherein said prevention comprises the prevention of tobacco smoking-induced immunosuppression associated with a degradation of interferon receptors in smokers, and said treatment is directed to overcome a resistance to interferon therapy in smokers.

5. The use~~method~~ of claim 1, wherein the interferon receptors are interferon α (IFNα) and/or interferon β (IFNβ) receptors.

6. The use~~method~~ of claim 1, wherein the medicament~~glutaryl histamine~~ is administered in a solid

form, and a duration of the administration is from 5 days to 12 months.

7. The use~~method~~ of any one of claims 1 to 6, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof in the medicament is from 0.1 to 100 mg/kg of human body weight per day, preferably from 0.1 to 30 mg/kg, more preferably from 0.3 to 10 mg/kg when administered one or more times per day.

8. The use~~method~~ of any one of claims 1 to 6, wherein a single dose of glutaryl histamine in the medicament is 100 mg.

9. Use of an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~A method~~ for preventing and/or treating a disease selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis~~, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof~~.

10. The use~~method~~ of claim 9, wherein the medicament~~glutaryl histamine~~ is administered in a solid form, and a duration of the administration is from 5 days to 12 months.

11. The use~~method~~ of claim 9 or 10, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof in the medicament is from 0.1 to 100 mg/kg of human body weight per day, preferably from 0.1 to 30 mg/kg, more

preferably from 0.3 to 10 mg/kg when administered one or more times per day.

12. A pharmaceutical composition for prevention and/or treatment of a disease associated with a reduced density of interferon receptors, the composition comprising an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 12, wherein said disease is selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis.

14. The pharmaceutical composition of claim 12, wherein said prevention and/or treatment is performed by overcoming a resistance to therapy with interferon and/or by compensating a reduced expression level of interferon receptors in a long-term therapy with interferon.

15. The pharmaceutical composition of claim 12, wherein the interferon receptors are interferon α (IFNα) and/or interferon β (IFNβ) receptors.

16. The pharmaceutical composition of claim 12, wherein glutaryl histamine is in a solid dosage form.

17. The pharmaceutical composition of any one of claims 12-16, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof is from 0.1 to 100 mg/kg of human body weight per day, preferably from 0.1 to 30 mg/kg, more preferably from 0.3 to 10 mg/kg when administered one or more times per day.

18. A kit for prevention and/or treatment of a disease selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis, the kit comprising a composition of any one of claims 12 to 16 and instructions for use thereof.

~~By proxy~~